Moreover, the 36-month beta value for FATE is 2.25. Analysts have varying opinions on the stock, with 4 analysts rating it as a “buy,” 2 as “overweight,” 12 as “hold,” and 0 as “sell.”
The public float for FATE is 97.88M and currently, short sellers hold a 12.97% of that float. On February 05, 2025, FATE’s average trading volume was 3.20M shares.
FATE) stock’s latest price update
The stock price of Fate Therapeutics Inc (NASDAQ: FATE) has surged by 10.69 when compared to previous closing price of 1.31, but the company has seen a 10.69% gain in its stock price over the last five trading sessions. seekingalpha.com reported 2025-02-04 that Fate Therapeutics uses iPSC and gene editing to offer scalable off-the-shelf therapies that could help oncology and immunology patients. Their pipeline has 3 interesting Phase 1 candidates for SLE, Solid Tumors, and B-cell lymphoma. But in my view, FT819 shows the most promising, as they recently achieved remission for one SLE patient.
FATE’s Market Performance
Fate Therapeutics Inc (FATE) has seen a 10.69% rise in stock performance for the week, with a -19.44% decline in the past month and a -40.33% plunge in the past quarter. The volatility ratio for the week is 7.78%, and the volatility levels for the past 30 days are at 9.18% for FATE. The simple moving average for the last 20 days is 6.30% for FATE stock, with a simple moving average of -54.06% for the last 200 days.
Analysts’ Opinion of FATE
Piper Sandler, on the other hand, stated in their research note that they expect to see FATE reach a price target of $6, previously predicting the price at $4. The rating they have provided for FATE stocks is “Overweight” according to the report published on June 17th, 2024.
Wells Fargo gave a rating of “Equal Weight” to FATE, setting the target price at $6 in the report published on March 27th of the previous year.
FATE Trading at -20.66% from the 50-Day Moving Average
After a stumble in the market that brought FATE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -83.58% of loss for the given period.
Volatility was left at 9.18%, however, over the last 30 days, the volatility rate increased by 7.78%, as shares sank -24.34% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -36.27% lower at present.
During the last 5 trading sessions, FATE rose by +8.00%, which changed the moving average for the period of 200-days by -71.93% in comparison to the 20-day moving average, which settled at $1.3622. In addition, Fate Therapeutics Inc saw -12.12% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at FATE starting from Bressi Jerome Charles, who sale 5,980 shares at the price of $1.55 back on Jan 10 ’25. After this action, Bressi Jerome Charles now owns 270,203 shares of Fate Therapeutics Inc, valued at $9,269 using the latest closing price.
TAHL CINDY sale 5,654 shares at $1.55 during a trade that took place back on Jan 10 ’25, which means that TAHL CINDY is holding 336,707 shares at $8,764 based on the most recent closing price.
Stock Fundamentals for FATE
Current profitability levels for the company are sitting at:
- -14.62 for the present operating margin
- -2.3 for the gross margin
The net margin for Fate Therapeutics Inc stands at -13.25. The total capital return value is set at -0.43. Equity return is now at value -46.59, with -34.32 for asset returns.
Based on Fate Therapeutics Inc (FATE), the company’s capital structure generated 0.21 points at debt to capital in total, while cash flow to debt ratio is standing at -1.33. The debt to equity ratio resting at 0.27. The interest coverage ratio of the stock is -20.25.
Currently, EBITDA for the company is -172.23 million with net debt to EBITDA at -0.34. When we switch over and look at the enterprise to sales, we see a ratio of 16.91. The receivables turnover for the company is 3.26for trailing twelve months and the total asset turnover is 0.03. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.29.
Conclusion
To wrap up, the performance of Fate Therapeutics Inc (FATE) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
